MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-19-2022
Country |
 Schweden |
IPO year |
2020 |
Industry |
Drug manufacturers |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
50.8 M |
Market Cap[1] |
$ 2.03 B |
EBITDA (LTM) |
$ -585 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Drug manufacturers"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
- | - | $ 754 M | Nasdaq Global Market,SPB |  USA |
 |
Agile Therapeutics
AGRX
|
- | 10.11 % | $ 58.2 M | Nasdaq Capital Market | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
- | 0.12 % | $ 2.06 B | Nasdaq Global Select Market |  France |
 |
Alimera Sciences
ALIM
|
- | - | $ 142 M | Nasdaq Global Market | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
- | 0.86 % | $ 117 M | Nasdaq Capital Market | USA |
 |
Canopy Growth Corporation
CGC
|
- | -3.21 % | $ 114 M | Nasdaq Global Select Market |  Canada |
 |
Cronos Group
CRON
|
- | -1.32 % | $ 1.35 B | Nasdaq Global Market | Canada |
 |
Catalent
CTLT
|
- | - | $ 11.5 B | NYSE,SPB | USA |
 |
Eagle Pharmaceuticals
EGRX
|
- | -39.89 % | $ 27.7 M | Nasdaq Global Market,SPB | USA |
 |
Endo International plc
ENDP
|
- | - | $ 28.9 M | Nasdaq Global Select Market,SPB |  Irlanda |
 |
Cumberland Pharmaceuticals
CPIX
|
- | 1.17 % | $ 55 M | Nasdaq Global Select Market | USA |
 |
HEXO Corp.
HEXO
|
- | 2.45 % | $ 38.1 M | NYSE | Canada |
 |
Evoke Pharma
EVOK
|
- | - | $ 36.6 M | Nasdaq Capital Market | USA |
 |
DURECT Corporation
DRRX
|
- | - | $ 50.1 M | Nasdaq Capital Market | USA |
 |
Emergent BioSolutions
EBS
|
$ 11.07 | - | $ 567 M | NYSE,SPB | USA |
 |
Athenex
ATNX
|
- | -23.39 % | $ 1.76 M | Nasdaq Global Select Market | USA |
 |
Jupiter Wellness
JUPW
|
- | - | $ 33.6 M | Nasdaq Global Select Market | USA |
 |
Evolus
EOLS
|
$ 4.35 | - | $ 270 M | Nasdaq Global Market | USA |
 |
China Pharma Holdings
CPHI
|
- | -2.39 % | $ 11.4 M | NYSE American |  China |
 |
Harrow Health
HROW
|
$ 49.44 | 3.63 % | $ 1.61 B | Nasdaq Global Market | USA |
 |
Pacira BioSciences
PCRX
|
$ 21.69 | 2.05 % | $ 1 B | Nasdaq Global Select Market,SPB | USA |
 |
Perrigo Company plc
PRGO
|
$ 14.49 | 0.59 % | $ 1.99 B | NYSE | USA |
 |
OrganiGram Holdings
OGI
|
$ 1.33 | - | $ 402 M | Nasdaq Global Select Market | Canada |
 |
Lannett Company
LCI
|
- | 1.15 % | $ 7.11 M | NYSE | USA |
 |
Bausch Health Companies
BHC
|
- | - | $ 2.22 B | NYSE | Canada |
 |
Sundial Growers
SNDL
|
$ 1.51 | 1.01 % | $ 3.37 M | Nasdaq Global Select Market | Canada |
 |
Tilray
TLRY
|
$ 7.54 | - | $ 4.66 B | Nasdaq Global Select Market | Canada |
 |
Neoleukin Therapeutics
NLTX
|
- | - | $ 193 M | Nasdaq Global Select Market | Canada |
 |
Organogenesis Holdings
ORGO
|
- | -2.73 % | $ 492 M | Nasdaq Capital Market | USA |
 |
cbdMD
YCBD
|
$ 0.75 | -6.86 % | $ 3.23 M | NYSE American | USA |
 |
PetIQ
PETQ
|
- | 1.64 % | $ 400 M | Nasdaq Global Select Market,SPB | USA |
 |
Aurora Cannabis
ACB
|
- | -3.23 % | $ 86.3 M | NYSE | Canada |
 |
ProPhase Labs
PRPH
|
- | - | $ 5.07 M | Nasdaq Capital Market | USA |
 |
Radius Health
RDUS
|
- | - | $ 1.42 B | Nasdaq Global Market | USA |
 |
Recro Pharma
REPH
|
- | -4.76 % | $ 65.3 M | Nasdaq Global Select Market | USA |
 |
Rockwell Medical
RMTI
|
$ 1.08 | -1.38 % | $ 25.2 M | Nasdaq Global Market | USA |
 |
Relmada Therapeutics
RLMD
|
- | - | $ 120 M | Nasdaq Global Select Market,SPB | USA |
 |
OptiNose
OPTN
|
- | - | $ 1.08 B | Nasdaq Global Select Market | USA |
 |
Assertio Holdings
ASRT
|
- | 2.31 % | $ 849 M | Nasdaq Capital Market | USA |
 |
PLx Pharma
PLXP
|
- | -27.8 % | $ 2.56 M | Nasdaq Capital Market | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
- | - | $ 3.52 M | Nasdaq Capital Market | USA |
 |
Solid Biosciences
SLDB
|
- | - | $ 261 M | Nasdaq Global Select Market,SPB | USA |
 |
SCYNEXIS
SCYX
|
$ 0.81 | - | $ 38.8 M | Nasdaq Global Select Market | USA |
 |
Veru
VERU
|
- | 3.03 % | $ 321 M | Nasdaq Capital Market | USA |
 |
Tricida
TCDA
|
- | - | $ 3.25 M | Nasdaq Global Select Market,SPB | USA |
 |
TherapeuticsMD
TXMD
|
$ 2.32 | -2.52 % | $ 24.2 M | Nasdaq Global Select Market | USA |
 |
Viatris
VTRS
|
- | - | $ 19.4 B | Nasdaq Global Select Market,SPB | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
- | 7.5 % | $ 6.35 M | Nasdaq Global Market | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
- | - | $ 55.5 M | Nasdaq Global Market,SPB | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.